GlassScriptPhysician profile
Stephen Mark Zaacks
NPI 1225052327
$6,846.50
in general payments reported to CMS, 2019-2025
35 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,121 · 2020: $695 · 2021: $542 · 2022: $547 · 2023: $889 · 2024: $1,231 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,941.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,470.30 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $806.68 | 2019-2025 | |
| Edwards Lifesciences Corporation | $631.59 | 2019-2021 | |
| Boston Scientific Corporation | $496.40 | 2019-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon |
| Abbott Laboratories | $455.69 | 2022-2025 | Mitraclip, Cardiomems, Coroflow |
| Janssen Pharmaceuticals, INC | $414.58 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.98 | 2019-2024 | Jardiance |
| Medtronic, INC. | $298.60 | 2021-2025 | Symplicity G3 |
| Pfizer INC. | $290.33 | 2019-2025 | |
| Amgen INC. | $230.47 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $202.37 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $189.35 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.88 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $141.82 | 2019-2025 | Eliquis, Camzyos |
| Regeneron Healthcare Solutions, INC. | $91.72 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $87.38 | 2023 | |
| Teleflex LLC | $77.30 | 2023-2025 | Trapliner, Turnpike, Orsiro Mission |
| Novo Nordisk INC | $58.30 | 2022-2025 | Wegovy |
| Lundbeck LLC | $45.51 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $41.09 | 2023-2024 | Inpefa |
| Shockwave Medical, INC | $38.06 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $35.06 | 2020 | |
| Alnylam Pharmaceuticals INC. | $26.62 | 2025 | Onpattro |
| Terumo Medical Corporation | $25.82 | 2019 | |
| Bridgebio Pharma, INC. | $23.27 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $21.03 | 2024 | Uptravi |
| Akcea Therapeutics, INC. | $20.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.35 | 2020 | |
| Livanova USA, INC. | $16.84 | 2021 | |
| Astellas Pharma US INC | $14.67 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.08 | 2019 | |
| Amarin Pharma, INC. | $13.56 | 2019 | |
| Biocompatibles, INC. | $12.12 | 2019 | |
| Tactile Systems Technology INC | $12.06 | 2019 | |
| Cardinal Health 200 LLC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Zaacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.